Introduction
Indolealkylamine xenobiotics are serotonin (5-HT) analogs that have high impact as substances of abuse (Yu, 2008; Halberstadt and Geyer, 2011) , except that a subgroup of indolealkylamines namely triptans are used to treat migraine (Kelley and Tepper, 2012) . Some newer indolealkylamine club drugs include 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT or by the street name "5-MEO") and 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DiPT or "Foxy"
and "Foxy methoxy") that were placed into Schedule I Controlled Substances by the United States Drug Enforcement Administration in 2011 and 2004 , respectively (DEA, 2004 DEA, 2010) . It is noteworthy that 5-MeO-DMT is an "endotoxin" because of its presence within the human body (Barker et al., 2012) . 5-MeO-DMT is also an active ingredient in a number of hallucinogenic animal and plant preparations such as the venom of Colorado River Bufo alvarius, virola snuffs and Ayahuasca beverage for medical, religious or recreational uses (Ott, 2001; McKenna, 2004) . Although the trafficking, distribution and abuse of 5-MeO-DMT are likely underreported because it was not a controlled drug before 2011, the System to Retrieve Information from Drug Evidence revealed 23 cases involving 35 drug exhibits identified as 5-MeO-DMT from 1999 to 2009, and the National Forensic Laboratory Information System documented 27 State and local drug cases involving 32 drug exhibits identified as 5- MeO-DMT from 2004 to 2009 (DEA, 2010 . With the epidemic of abuse, indolealkylamine intoxications have been frequently reported in hospitals in recent years including several deaths associated with the abuse of 5-MeO-DMT and 5-MeO-DiPT (Brush et al., 2004; Sklerov et al., 2005; 2011b) as well as i.v. and i.p. administration of harmaline (5 or 15 mg/kg) alone (Wu et al., 2009 ). In the present study, 0.2-0.3 mL of blood sample was collected from one mouse at various time points (15-255 min, N = 4 per time point), and each mouse was sampled once. Serum was prepared with a serum separator (Becton Dickinson, Franklin Lakes, NJ) and stored at -80°C until the quantification of harmaline, 5-MeO-DMT and bufotenine concentrations by liquid chromatography tandem mass spectrometry (LC-MS/MS).
It is noteworthy that higher dose combinations, namely 5 and 15 mg/kg of harmaline plus 10 mg/kg of 5-MeO-DMT resulted in obvious toxicity in mice. Therefore, the PK experiments were terminated at 105 and 45 min, respectively, when animals showed signs of dying. The serum profiles of harmaline, 5-MeO-DMT and bufotenine of these dose combinations determined experimentally were used for validating the final PK DDI model.
Brain Drug Distribution.
Experiments were conducted as previously reported (Shen et al., 2011b) . Briefly, wild-type and Tg-CYP2D6 mice (N = 4 per time point) were euthanized at various time points after drug administration. Whole brain was immediately removed from the skull, rinsed, homogenized with ice-cold saline, and stored at -80°C until the quantification of 5-MeO-DMT and bufotenine by LC-MS/MS. The contribution of residual blood in the brain tissue to the brain concentration was corrected by subtracting 3.7% of the serum drug concentration from the corresponding brain concentration (Khor et al., 1991) .
Drug Metabolism by Purified CYP2D6. Enzyme incubations were carried out as reported using purified CYP2D6.1 enzyme (Yu et al., 2002; Jiang et al., 2009; Zhang et al., 2009) . In This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on February 7, 2013 as DOI: 10.1124 at ASPET Journals on July 6, 2017 dmd.aspetjournals.org Downloaded from particular, each reaction was incubated in 100 mM of potassium phosphate buffer (pH 7.4) in a final volume of 200 μ L at 37°C for 20 min, which consisted of 0.02 µM of CYP2D6.1, 0.2 µM of P450 reductase, 10 µg of dilauroylphosphatidylcholine, 2 or 10 µM of 5-MeO-DMT in the absence or presence of harmaline (2 or 20 µM). All reactions were initiated by the addition of NADPH (1 mM of final concentration) and terminated by 5 µL of 70% perchloric acid. All reactions were conducted in duplicate. The mixture was centrifuged at 14,000 rpm for 5 min, and the supernatant was directly injected for HPLC analysis.
HPLC and LC-MS/MS Analyses. Bufotenine concentrations within enzyme incubations with
5-MeO-DMT were determined by HPLC analyses. The Agilent 1100 series HPLC system (Palo Alto, CA) consisted of an online vacuum degasser, quaternary pump, autosampler, thermostat controlled column compartment, fluorescence detector and diode-array detector, and the instrument was controlled by Agilent ChemStation software. 5-MeO-DMT and bufotenine were separated with a Regis REXCHROM phenyl column (250 mm × 4.6 mm, 5 µm; Morton Grove, IL) under the conditions described previously (Yu et al., 2003a) . The calibration linear ranges for 5-MeO-DMT and bufotenine were 2-100 pmol on-column. Inter-day and intra-day coefficients of variation were less than 10% for both analytes.
Blood and brain drug and metabolite concentrations were determined by a validated LC-MS/MS method (Shen et al., 2009; Shen et al., 2011b) . A simple protein precipitation and liquid-liquid extraction method was used for the processing of serum and brain samples, respectively. In particular, 60 µL of ice-cold acetonitrile containing 50 nM of 5-Me-DMT (internal standard) was added to 20 µL of serum sample for protein precipitation. After 10 min centrifugation at 14,000
This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on February 7, 2013 as DOI: 10.1124 at ASPET Journals on July 6, 2017 dmd.aspetjournals.org Downloaded from rpm, the supernatant was subject to LC-MS/MS analysis. For brain drug concentrations, 50 µL of brain homogenate was mixed with 5 µL of sodium hydroxide (1 M) and 10 µL of 5-Me-DMT (100 nM) and the mixture was extracted with 1 mL of ethyl acetate. After the centrifugation at 14,000 rpm for 5 min, the supernatant was transferred to a new vial and evaporated to dryness.
The residue was reconstituted in 50 µL of 50% methanol, centrifuged at 14,000 rpm for 5 min, and transferred to a new vial for LC-MS/MS analysis. Separation of analytes was achieved with a Phenomenex phenyl-hexyl column (50 mm × 4.6 mm, 3 µm, Torrance, CA). LC-MS/MS quantification was conducted with an API 3000 turbo ionspray ionization triple-quadrupole mass spectrometer (Applied Biosystems, Foster City, CA) coupled to a Shimadzu prominence HPLC system (Kyoto, Japan).
Pharmacokinetic Modeling. Noncompartmental analyses were performed with Phoenix
WinNonlin version 6.1 (Pharsight, Mountain View, CA). The maximum serum concentrations (C max ) were the observed values between the first and last measured time points without interpolation. The area under the concentration-time curve from the start to the last measured time point (AUC 0→t ) was calculated by the linear trapezoidal method. AUC 0→∞ was estimated by extrapolation from AUC 0→t with the addition of C last /λ, where C last is the last measured concentration and λ is the apparent terminal slope of linear regression from semi-logarithmic concentration-time curve.
To better understand the PK interactions between harmaline and 5-MeO-DMT as well as the pharmacodynamics (unpublished data), a mathematical model was proposed to characterize serum harmaline, 5-MeO-DMT and bufotenine PK. In our previous single-dose PK studies, twoThis article has not been copyedited and formatted. The final version may differ from this version. compartmental models with first order absorption and linear or capacity-limited elimination from the central compartments have been established to describe the PK properties of harmaline and 5-MeO-DMT, respectively (Wu et al., 2009; Shen et al., 2011b) . These models were adopted into the present study with modifications to characterize the PK profiles of harmaline and 5-MeO-DMT under the DDI condition. The model was also extended to include the PK of bufotenine,
the O-demethylated metabolite of 5-MeO-DMT. Although the PK profile of bufotenine after i.v.
administration is not available in our study, literature data indicate that this compound exhibits polyexponential PK in rats after i.v. injection (Sanders and Bush, 1967) . Therefore, bufotenine PK profiles after i.p. administration of 5-MeO-DMT were fitted to a two-compartment model with linear elimination from its central compartment, assuming that bufotenine was only generated in the central compartment from parent drug, and bufotenine formed from 5-MeO-DMT all entered into the systemic circulation without first-pass elimination at the site of formation. The final model ( Fig. 1 ) was chosen based on the goodness-of-fit criteria, including
Akaike's Information Criterion (AIC), Schwarz Criterion (SC), coefficient variation of the estimates (CV%) and visual inspection of the fitted profiles.
Harmaline PK was defined by the following differential equations: In Tg-CYP2D6 mice:
In wild-type mice:
The PK model for 5-MeO-DMT in wild-type and Tg-CYP2D6 mice is defined according to the following equations:
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The total systemic clearance (CL M ) of 5-MeO-DMT is different in two genotypes of mice:
In Tg-CYP2D6 mice:
In wild-type mice: Fig. 1) , according to the known mechanisms (Kim et al., 1997; Zhao et al., 2011) .
The rate of change in bufotenine concentrations in wild-type and Tg-CYP2D6 mice is defined by the following two differential equations:
The input function for equation 13 is different in two genotypes of mice:
In wild-type mice: 
Results

CYP2D6
status has a significant impact on serum harmaline pharmacokinetics. To investigate the PK interactions of harmaline and 5-MeO-DMT, it is necessary to examine harmaline PK. We have recently defined harmaline pharmacokinetic profiles in mouse models following i.v. and i.p. administration (Wu et al., 2009) . In this study, serum harmaline concentrations were also monitored over time after coadministration of harmaline and 5-MeO-DMT ( Fig. 2A, 2B , 3A and 3B), although 5-MeO-DMT unlikely alters harmaline PK. Consistent with our previous findings (Wu et al., 2009 ), elimination of harmaline was faster in Tg-CYP2D6 mice ( Fig. 2A , 2B, 3A and 3B), given the fact that Tg-CYP2D6 mice exhibit CYP2D6-mediated metabolism besides intrinsic murine elimination capacity. Consequently, systemic exposure to harmaline (AUC) was about 1-fold higher in wild-type mice than that in Tg-CYP2D6 mice treated with the same doses of harmaline and 5-MeO-DMT (Table 1) , supporting the importance of CYP2D6 genetic polymorphism in harmaline metabolism and pharmacokinetics (Yu et al., 2003b; Wu et al., 2009 ).
Coadministration of MAOI harmaline significantly increases the systemic exposure to 5-
MeO-DMT, which may be further affected by CYP2D6 status at some dose combinations.
To delineate the PK interactions between harmaline and 5-MeO-DMT as well as the potential impact of CYP2D6, various dose combinations of harmaline (2, 5 or 15 mg/kg) and 5-MeO-DMT (2 or 10 mg/kg) were tested in wild-type and Tg-CYP2D6 mice ( Fig. 2 and 3 ), in addition to i.v. and i.p. administration of 5-MeO-DMT alone (Fig. 4) . Our data revealed that coadministration of MAOI harmaline reduced 5-MeO-DMT elimination, leading to a significantly greater systemic exposure (AUC) to 5-MeO-DMT (Table 2 ). For instance, the This article has not been copyedited and formatted. The final version may differ from this version. and wild-type mice, respectively. When 2 mg/kg of MAOI harmaline was co-administered, these values increased to 71.1 ± 13.3 and 97.6 ± 12.2 μ mol/L⋅min, respectively ( Table 2 ). The results highlight the critical role of MAO-A in 5-MeO-DMT pharmacokinetics.
The impact of harmaline on 5-MeO-DMT PK can be further influenced by CYP2D6 that determines harmaline PK, although CYP2D6 has minimal effect on the PK of 5-MeO-DMT administered alone (Fig. 4 ). For instance, coadministration of 5 mg/kg of harmaline increased the exposure to 5-MeO-DMT (10 mg/kg) (AUC 15 min→∞ for 5-MeO-DMT alone versus AUC 15→105 min for 5-MeO-DMT plus harmaline) to a greater extent in wild-type mice (227 ± 41 versus 759 ± 91 μ mol/L⋅min) than Tg-CYP2D6 mice (249 ± 46 versus 571 ± 11 μ mol/L⋅min) ( Table 2 ). This is also manifested by the C max values (Table 2) . Together, our results indicate a possible complication of harmaline-5-MeO-DMT DDI by CYP2D6, likely through its action on harmaline PK ( Fig. 2A , 2B, 3A and 3B).
Harmaline shows a dose-dependent biphasic effect on CYP2D6-catalyzed 5-MeO-DMT O-
demethylation, due to the capacity of harmaline in inhibition of CYP2D6 enzymatic activity.
Serum bufotenine concentrations were also determined to define the impact of harmaline on 5-MeO-DMT O-demethylation that is mediated by CYP2D6 enzyme (Yu et al., 2003a; Shen et al., 2010b) . In both wild-type and Tg-CYP2D6 mice, coadministration of a lower dose (5 mg/kg) of harmaline significantly increased bufotenine production from 5-MeO-DMT. This is manifested by a greater C max and AUC values in mice co-administered with 5 mg/kg of harmaline as compared with 5-MeO-DMT alone (Table 3) . Surprisingly, further increase of harmaline dose This article has not been copyedited and formatted. The final version may differ from this version. did not show a dose-dependent increase in bufotenine formation. Instead, bufotenine concentrations and overall AUC were decreased in all mice when the harmaline dose was increased from 5 to 15 mg/kg ( Fig. 2E and 2F ; Table 3 ). For instance, the systemic exposure to bufotenine produced from 2 mg/kg of 5-MeO-DMT was reduced from 16.3 ± 1.4 to 5.16 ± 0.76 µmol/L⋅min in wild-type mice and from 18.0 ± 1.5 to 6.86 ± 1.33 µmol/L⋅min in Tg-CYP2D6 mice, respectively, when harmaline dose was increased from 5 to 15 mg/kg (Table 3 ). This suggests a dose-dependent biphasic influence of harmaline on bufotenine formation from 5-
Working with the hypothesis that higher concentrations of harmaline might inhibit 5-MeO-DMT O-demethylation, we conducted an enzymatic study to assess whether harmaline inhibits CYP2D6 activity in vitro in the production of bufotenine from 5-MeO-DMT. 2 and 10 µM of 5-MeO-DMT in the absence and presence of 2 or 10 µM of harmaline were tested because such concentrations were relevant to the blood drug concentrations ( Fig. 2 and 3 ). Our data showed that indeed harmaline was able to inhibit bufotenine formation from 5-MeO-DMT in a dosedependent manner (Fig. 5 ). Co-incubation of 2 µM of harmaline showed approximately 50% and 25% reduction in bufotenine production from 2 and 10 µM of 5-MeO-DMT, respectively. When harmaline concentration was increased to 10 µM, the extent of inhibition was about 75% and 50%, respectively (Fig. 5) . The results support the hypothesis that harmaline is not only a CYP2D6 substrate but also an inhibitor, and its inhibitory action on CYP2D6 enzyme shown in vitro ( Fig. 5 ) might explain the in vivo suppression of bufotenine formation from 5-MeO-DMT by higher dose levels of harmaline (15 mg/kg) ( Table 3) .
This article has not been copyedited and formatted. The final version may differ from this version. To evaluate the final model (Fig. 1 ), blood harmaline, 5-MeO-DMT and bufotenine PK profiles ( Fig. 3) were simulated using the final PK parameters (Table 4) for the treatments of 5 or 15 mg/kg of harmaline plus 10 mg/kg of 5-MeO-DMT, which induced an obvious toxicity in mice.
The model (Fig. 1 ) nicely predicted the PK profiles at early time points (15-45 min; Fig. 3 ), but
showed some bias at later time points (75-105 min; Fig. 3 ), which might be attributed to the physiological changes under such toxic dose combinations of 5-MeO-DMT and harmaline.
These results suggest that this DDI model may be employed to define the PK interactions of harmaline and 5-MeO-DMT at various dose levels and identify the potential influence of CYP2D6 pharmacogenetics.
Coadministration of MAOI harmaline sharply elevates 5-MeO-DMT and bufotenine accumulation in mouse brain. Given the fact that 5-MeO-DMT acts on the central nervous system, we further examined the impact of MAOI harmaline on brain 5-MeO-DMT accumulation. Our data showed that concurrent harmaline substantially increased brain 5-MeO-DMT concentrations (Fig. 6 ) as well as the metabolite bufotenine concentrations (Fig. 7) at various time points, as compared to treatment with 5-MeO-DMT alone (Shen et al., 2011b) . For instance, a small dose (5 mg/kg) of harmaline led to a more than 10-fold increase in 5-MeO-DMT accumulation in mouse brain and a prolonged cerebral exposure to the drug (Fig. 6 ).
Consistent with the findings on systemic drug exposure ( 
Discussions
The present study systemically evaluates the pharmacokinetic interactions between harmaline and 5-MeO-DMT at multiple dose levels. The mechanistic effects of harmaline on 5-MeO-DMT PK are comprised of the inhibitions of MAO-A-mediated deamination and CYP2D6-catalyzed O-demethylation, which together results in a dose-dependent biphasic effect on the production of active metabolite bufotenine. The inhibition of MAO-A-controlled metabolic elimination inevitably leads to a significantly greater and prolonged systemic and brain exposure to 5-MeO-DMT, which can be further influenced by CYP2D6 status at certain dose combinations. In addition, a mathematical model is developed to describe the PK interactions of harmaline and 5-MeO-DMT including the PK of the active metabolite bufotenine and the impact of CYP2D6
status.
Harmaline is a competitive inhibitor to MAO-A, with an in vitro K i value of 0.048 µM in suppression of MAO-A enzyme activity (Kim et al., 1997) . Data from the present study show that, in both wild-type and Tg-CYP2D6 mice, blood harmaline concentrations are generally much higher than the K i value ( Fig. 2A , 2B, 3A and 3B). Given the fact that the lowest dose (2 mg/kg) of harmaline tested in this study is actually lower than the human equivalent dose (5 mg/kg) (Ott, 2001; Riba et al., 2003; Yuruktumen et al., 2008) , a complete inhibition of MAO-A by harmaline might occur and it is expected to alter the PK of 5-MeO-DMT or other MAO-A substrate drugs in humans. Second, the complete blockage of MAO-A activity in mice treated with various doses of harmaline (e.g., 2, 5 and 15 mg/kg) plus the same dose of 5-MeO-DMT (e.g., 2 mg/kg) is also supported by the observation of similar blood 5-MeO-DMT C max values (e.g., about 1.9 µM; systemic exposure to the same dose of 5-MeO-DMT ( Table 2 ) that is likely attributed to the prolonged inhibition of MAO-A by higher doses of harmaline ( Fig. 2 and 3 ). This observation also agrees with our finding that the increase of systemic exposure to 5-MeO-DMT is more pronounced in wild-type mice than that in Tg-CYP2D6 mice (Table 2) , consistent with a longer and greater exposure to the MAO-A inhibitor harmaline itself in wild-type mice lacking CYP2D6 activity ( Fig. 2 and 3 ; Table 2 ).
Current study presents an interesting observation of in vivo inhibition of bufotenine formation from 5-MeO-DMT with the increase of harmaline dose from 5 to 15 mg/kg. The suppression of bufotenine production from 5-MeO-DMT by harmaline is supported by in vitro enzymatic study using purified CYP2D6 (Fig. 5) . The inhibitory effect of harmaline on CYP2D6-catalyzed 5-MeO-DMT O-demethylation is incorporated in the final model ( Fig. 1 ) that describes harmaline-5-MeO-DMT PK interactions. The estimated in vivo inhibition potency for harmaline inhibition of CYP2D6-catalyzed 5-MeO-DMT O-demethylation is 7.13 µM (Table 4) , which is relatively lower than the Ki value (26.2 µM) for harmaline competitive inhibition of CYP2D6-mediated dextromethorphan O-demethylation (Zhao et al., 2011) . This might be due to the difference in experimental systems and substrates. Nevertheless, harmaline itself is also metabolized by CYP2D6, which is considered in the final PK model that likely provides a more accurate estimation of the in vivo Ki value.
The integrated PK model ( Fig. 1) exposure to bufotenine (Table 3) . However, further increases in harmaline dose (e.g., 15 mg/kg) actually reduces the production of bufotenine as harmaline itself inhibits CYP2D6 activity ( Fig.   5 ) (Zhao et al., 2011) . Second, comparison of the serum PK profiles of 5-MeO-DMT and bufotenine from multiple harmaline-5-MeO-DMT dose combinations indicates that bufotenine generally accounts for less than 10% of the parent drug 5-MeO-DMT (Table 2 and 3) . Third, compared to the pronounced 5-MeO-DMT penetration through the blood-brain barrier (BBB) (McBride, 2000) that is indicated by a 2-to 4-fold higher 5-MeO-DMT concentration in mouse brain ( Fig. 6 ) than that in blood (Fig. 2, 3 and 4), bufotenine has a poor capacity to cross the BBB (McBride, 2000) which is manifested by a 10-25% of blood bufotenine concentration (Fig. 2, 3 and 4) appearing in mouse brain (Fig. 7) . Therefore, it may be concluded that the contribution of active metabolite bufotenine to the overall effects of harmaline-5-MeO-DMT DDI is likely limited to its high affinity to the peripheral 5-HT 2A receptor (Cook et al., 1994; Lesurtel et al., 2006) .
With the increase of 5-MeO-DMT concentrations following the inhibition of MAO-A by harmaline, blood (Fig. 2, 3 and 4) and brain ( Fig. 7) bufotenine concentrations are generally
Increased. The production of bufotenine from 5-MeO-DMT is determined by CYP2D6 enzyme (Yu et al., 2003a) . Indeed, bufotenine concentrations are typically greater in Tg-CYP2D6 mice that exhibit additional CYP2D6 activity, and the difference reaches statistical significance at certain dose combinations such as 10 mg/kg of 5-MeO-DMT plus 5 mg/kg of harmaline (Table 3 ; (Table 4) . A greater bioavailability with increasing harmaline dose levels might be explained by the substrate inhibition of its own O-demethylation elimination ( This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. 
